First FDA Approved treatment for molluscum Contagiosum : Ycanth.
As parents, we always strive to keep our children healthy and happy. However, when skin conditions like molluscum contagiosum strike, it can be distressing for both kids and parents alike. The good news is that the FDA has recently given its stamp of approval to a groundbreaking treatment called Ycanth (cantharidin) for molluscum contagiosum in children and adults. This development may offer renewed hope for families dealing with this viral skin infection.
Molluscum contagiosum is a common viral skin infection that leads to the appearance of small bumps on the skin. These bumps can be white, pink, or flesh-colored and may cause itching and irritation. They tend to occur in groups and can be found on various parts of the body, such as the face, neck, arms, legs, stomach, and genital area. This condition is typically transmitted through direct skin-to-skin contact and is more common in children under the age of 10. While molluscum contagiosum is generally harmless, it can be bothersome and affect a child's self-esteem.
The recent FDA approval of Ycanth, a topical solution containing cantharidin, brings new hope for families dealing with molluscum contagiosum. Ycanth is the first-ever FDA-approved treatment for this condition. Administered only by healthcare providers, the treatment involves applying Ycanth to the affected areas of the skin every three weeks, as needed.
The efficacy of Ycanth was established through rigorous clinical trials involving patients aged 2 to 60 years. In these trials, participants were randomized to receive either Ycanth or a placebo, With 54% of subjects treated with Ycanth achieving complete clearance of all treated molluscum bumps by day 84, compared to just 13% in the placebo group.
While Ycanth has shown impressive efficacy, it's essential to be aware of potential adverse reactions. The most common side effects occurred at the application site and included blistering, pain, itching, scabbing, reddening, discoloration, dryness, swelling, and skin erosion. To ensure the safety of the treatment, healthcare providers must administer Ycanth, and oral contact with the treatment area should be avoided after application. Additionally, Ycanth is flammable, even after drying, so precautions like avoiding fire, flame, or smoking near the treated area are crucial until the treatment is entirely removed.
The approval of Ycanth looks to be a significant milestone in the treatment of molluscum contagiosum with no other FDA approved treatments available.
Interested to learn more about gentle & natural support for molluscum? Find out more